Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Astellas exercised its option to acquire Potenza for $164.6m upfront plus up to $240.1m in milestones (~$405m), adding three clinical-stage immuno-oncology…
Astellas paid $164.6M upfront plus up to $240.1M in milestones for full Potenza ownership, gaining three IO candidates positioned for combinations with…
Astellas terminated ASP8374 after the Phase 1 study failed to meet criteria to continue, marking the first major writedown from the Potenza acquisition.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Astellas Pharma acquired the remaining outstanding shares of immuno-oncology partner Potenza Therapeutics for ~$165M upfront plus up to $240M in contingent milestones (~$405M total). Strengthens Astellas' immuno-oncology pipeline including TIGIT and GITR antibodies.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Astellas Pharma Inc. / Potenza Therapeutics, Inc. (this deal) | 2019 | $405M | — |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Astellas Pharma Inc. / Ganymed Pharmaceuticals | 2016 | $1.4B | 81 |
| Astellas Pharma Inc. / Sangamo Therapeutics, Inc. | 2026 | $50M | 63 |
| Astellas Pharma Inc. / Ogeda SA | 2017 | $850M | 59 |
| Astellas Pharma Inc. / Ocata Therapeutics, Inc. | 2015 | $379M | 41 |
| Astellas Pharma Inc. / Optimer Pharmaceuticals, Inc. | 2012 | $90M | 38 |
← Browse all deals · How we score deals
More: 2019 deals · Astellas Pharma Inc. deals · Oncology deals